Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 71 to 80 of 400 total matches.
Lipid-Lowering Drugs
The Medical Letter on Drugs and Therapeutics • Sep 19, 2022 (Issue 1659)
.
For further information call: 800-211-2769
The Medical Letter ® Vol. 64 (1659) September 19, 2022
146
when ...
Cholesterol management guidelines from the
American College of Cardiology/American Heart
Association Task Force were last published in 2019.
Opioids for Pain
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022 (Issue 1665)
formulation can be used in patients with
continuous severe pain.
The Medical Letter ® Vol. 64 (1665 ...
A new CDC guideline for prescribing opioids for pain
recently became available. Nonopioid drugs for pain
were reviewed in a previous issue.
Drugs for Anxiety Disorders
The Medical Letter on Drugs and Therapeutics • Aug 07, 2023 (Issue 1682)
abruptly. The frequency of
The Medical Letter ® Vol. 65 (1682) August 7, 2023
122
Table 1. SSRIs ...
Anxiety disorders (generalized anxiety disorder,
panic disorder, social anxiety disorder, and various
phobias) are the most common form of psychiatric
illness. They can be treated effectively with cognitive
behavioral therapy (CBT) and/or pharmacotherapy.
Med Lett Drugs Ther. 2023 Aug 7;65(1682):121-8 doi:10.58347/tml.2023.1682a | Show Introduction Hide Introduction
Drugs for COPD
The Medical Letter on Drugs and Therapeutics • Sep 02, 2024 (Issue 1710)
of exacerbations,
The Medical Letter ® Vol. 66 (1710) September 2, 2024
138
Table 1. Inhaled Drugs for COPD ...
The main goals of treatment of chronic obstructive
pulmonary disease (COPD) are to relieve symptoms,
reduce the frequency and severity of exacerbations,
prevent disease progression, and reduce mortality.
GOLD (Global Initiative for Chronic Obstructive Lung
Disease) guidelines for treatment of COPD were
updated recently. Treatment of acute exacerbations
is not discussed here. Drugs available for treatment
of COPD are listed in Tables 1 and 3.
Med Lett Drugs Ther. 2024 Sep 2;66(1710):137-44 doi:10.58347/tml.2024.1710a | Show Introduction Hide Introduction
Treatment of Allergic Rhinitis and Allergic Conjunctivitis
The Medical Letter on Drugs and Therapeutics • Mar 31, 2025 (Issue 1725)
prohibited.
For further information call: 800-211-2769
The Medical Letter ® Vol. 67 (1725) March 31, 2025 ...
Initial treatment of allergic rhinitis (AR) depends
on the severity of symptoms and whether they are
intermittent or persistent (see Table 1).
Med Lett Drugs Ther. 2025 Mar 31;67(1725):49-56 doi:10.58347/tml.2025.1725a | Show Introduction Hide Introduction
Sodium Sulfate-Based Tablets (Sutab) for Colonoscopy Preparation
The Medical Letter on Drugs and Therapeutics • Mar 08, 2021 (Issue 1619)
® Vol. 63 (1619) March 8, 2021
As with any bowel-cleansing preparation, Sutab can
reduce ...
The FDA has approved an oral tablet formulation of
sodium sulfate, magnesium sulfate, and potassium
chloride (Sutab – Braintree) for colon cleansing prior
to colonoscopy in adults. A sodium sulfate-based oral
solution (Suprep) has been available in the US since
2010. Sutab is the second tablet formulation to be
approved for bowel cleansing prior to colonoscopy;
a sodium phosphate-based tablet (OsmoPrep) was
approved earlier.
Nirsevimab (Beyfortus) for Prevention of Severe RSV Disease in Young Children
The Medical Letter on Drugs and Therapeutics • Sep 18, 2023 (Issue 1685)
randomized to receive nirsevimab 50 mg (5 kg) IM or placebo.7
The Medical Letter ® Vol ...
The FDA has approved nirsevimab-alip (Beyfortus –
AstraZeneca/Sanofi), a long-acting monoclonal
antibody, for the prevention of respiratory syncytial
virus (RSV) lower respiratory tract disease in
neonates and infants born during or entering their
first RSV season, and in children ≤24 months old who
are at increased risk for severe RSV disease through
their second RSV season. Nirsevimab is the first drug
to be approved for protection of all infants during
their first RSV season.
Med Lett Drugs Ther. 2023 Sep 18;65(1685):145-7 doi:10.58347/tml.2023.1685a | Show Introduction Hide Introduction
Lebrikizumab (Ebglyss) for Atopic Dermatitis
The Medical Letter on Drugs and Therapeutics • Nov 11, 2024 (Issue 1715)
, the primary endpoint,
a reduction in IGA score to 0 or 1 (denoting clear
The Medical Letter ® Vol. 66 (1715 ...
The FDA has approved lebrikizumab-lbkz (Ebglyss –
Lilly), a subcutaneously injected interleukin (IL)-13
antagonist, for treatment of moderate to severe
atopic dermatitis that has not been or cannot be
adequately treated with topical therapy in patients ≥12
years old (weight ≥40 kg). Lebrikizumab is the third
subcutaneously injected human IgG4 monoclonal
antibody to be approved in the US for this indication.
Tralokinumab (Adbry), another IL-13 antagonist, is
also approved for use in patients ≥12 years old, and
dupilumab (Dupixent), an IL-4 and IL-13 inhibitor, is
approved for...
Med Lett Drugs Ther. 2024 Nov 11;66(1715):179-81 doi:10.58347/tml.2024.1715b | Show Introduction Hide Introduction
In Brief: Sacubitril/Valsartan (Entresto) Expanded Indication
The Medical Letter on Drugs and Therapeutics • May 03, 2021 (Issue 1623)
://medicalletter.org/TML-article-1619e
66
The Medical Letter ® Vol. 63 (1623) May 3, 2021
Medical
Letter Entresto ...
The oral fixed-dose combination of the neprilysin
inhibitor sacubitril and the angiotensin receptor
blocker (ARB) valsartan (Entresto – Novartis) was
approved in 2015 to reduce the risk of cardiovascular
death and hospitalization for heart failure in adults with
chronic heart failure (NYHA Class II-IV) and reduced
ejection fraction (HFrEF; LVEF...
COVID-19 Update: FDA Narrows EUA for the Johnson & Johnson Vaccine
The Medical Letter on Drugs and Therapeutics • Jun 13, 2022 (Issue 1652)
, 2022.
The Medical Letter ® Vol. 64 (1652) June 13, 2022 COVID-19 vaccines Comirnaty Spikevax ...
The FDA has restricted its Emergency Use Authorization for the adenovirus-based COVID-19 vaccine manufactured by Johnson & Johnson (Janssen) to adults who are unable or unwilling to receive another COVID-19 vaccine. The mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) are preferred for all persons without a contraindication.